Stockpiling of Medicinal Products Workshop
21-22 February 2008, Luxembourg
Huge financial investments for purchasing and storing as well as meticulous preparations for distribution are required in the context of stockpiling of large quantities of medicinal products such as antivirals and vaccines for major health threats.
The specific characteristics of such threats, likely but not occurring regularly, poses several challenges for the public health authorities. Across the EU-27, several approaches have been worked out to deal with these questions.
The objective of the workshop was to exchange and learn from good practices. The workshop has gather participants, who address these issues on national level or on an international stage – members Health Security Committee, national Influenza coordinators, Commission services (DG SANCO Health Threats Unit and Health Measures Unit, DG Enterprise), European Medicines Agency (EMEA), European Centre for Disease Prevention and Control (ECDC), World Health Organisation Office for Europe, and the European Federation of Pharmaceutical Industries and Associations (EFPIA).
During the workshop participants presented lessons learnt from various cases, including antiviral use for children, and issues in distribution under the constraint to reach target populations in 24 hours. The workshop has also provided an opportunity for national stockpile managers to identify the potential need for new regulatory and technical developments.
- Antivirals: logistical challenges – an industry perspective, Catherine Steele, Roche, European Federation of Pharmaceutical Industries and Associations
- CHMP recommendations for the core risk management plan for pre-pandemic vaccines, Xavier Kurz Pharmacovigilance and Safety & Efficacy of Medicines, European Medicines Agency (EMEA), London
- EU antigen bank for FMD as an example for stockpiling of medicinal products, Magdalena Zietara, European Commission - DG Health and Consumers
- Influenza antiviral medicinal products for potential use during a pandemic, Anne-Sophie Henry-Eude, European Medicines Agency (EMEA), London
- Iodine tablets distribution as part of iodine prophylaxis in case of a nuclear accident in France Philippe Chappé - Project manager - Nuclear safety authority Directorate for environment protection and emergency preparedness
- Longetivity and Shelf life of stockpiled antivirals (bulk, packaged) versus antivirals sold via pharmacies for private Use, Jean-Louis ROBERT, Ph.D., Head Luxembourg OMCL Laboratoire National de Santé, Luxembourg
- Management principles of the global smallpox vaccine reserve, Dr. Daniel Lavanchy, WHO
- National stockpiles of health products, examples of actions conducted by a national agency, Marie-Hélène TISSIER, Agence Française de sécurité sanitaire de produits sante
- Office National d'indemnisation des accidents médicaux - presentation, Dominique Martin
- Optimization of distribution operations, Giovanni Righini, Università degli Studi di Milano
- Preparations in Sweden - Achieving 24h distribution of stockpiled antivirals, The National Board of Health and Welfare, Sweden
- Achieving 24h distribution of (stockpiled) vaccines - Preparations in Sweden, The National Board of Health and Welfare, Sweden
- Rapid deployment of the WHO Strategic Antiviral Stockpile, N. Shindo, WHO/EPR/GIP
- Stockpiling anthrax vaccines, Tim Brooks, Head of Novel & Dangerous Pathogens, Health Protection Agency, UK
- Stockpiling of H5N1 vaccines, Norbert W. Hehme, European Vaccine Manufacturers, Influenza Pandemic Working Group
- Targeting infection control to maximize the impact of a limited stockpile, Jacco Wallinga, National Institute for Public Health and the Environment, The Netherlands
- United Nations Humanitarian Response Depot (HRD) Network – presentation
- Vaccine stock management (cold chain) and distribution capacity in the Member States, Regine Kämmerer, MD, Ministry of Labour, Health and Social Affairs of the State of North Rhine-Westfalia, Germany